semaglutide and beta blockers Efficacy of Initiation of versus SGLT2 inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study For a type 2 diabetic
Description
63: S39-S62
Liraglutide 1.8 mg daily reduced 3-point MACE by 13% vs placebo (HR 0.87, 95% CI 0.78-0.97, p=0.01)
GLP-1 RA initiation was also associated with lower risk of nerve block procedures (risk ratio 0.87) and triptan prescriptions (risk ratio 0.87)
It is hoped that over the long-term, effects of GLP-1 analogs will preserve beta-cell function and increase beta-cell mass, a much-desired effect in type 2 diabetes patients
Tack, receiving grant support from AstraZeneca, advisory board fees from Merck, and lecture fees and advisory board fees from Novo Nordisk
